Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized study to assess the effect on response rate of MabThera (rituximab) added to a standard chemotherapy, Bendamustine or Chlorambucil, in patients with Chronic Lymphocytic Leukemia.

Trial Profile

A randomized study to assess the effect on response rate of MabThera (rituximab) added to a standard chemotherapy, Bendamustine or Chlorambucil, in patients with Chronic Lymphocytic Leukemia.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Bendamustine; Chlorambucil
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms MaBLe; RiBECCA
  • Sponsors Roche
  • Most Recent Events

    • 17 Jun 2022 Results meta-analysis of randomized controlled trials from NCT0101006, NCT01886872, NCT01056510, and NCT03336333, presented at the 27th Congress of the European Haematology Association
    • 07 Jun 2022 Results of meta-analysis of randomized controlled trials ((NCT01010061), ALLIANCE (NCT01886872), MABLE (NCT01056510), and SEQUOIA (NCT03336333)) assessing relative efficacy of zanubrutinib compared with standard frontline treatments for chronic lymphocytic leukemia, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
    • 30 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top